Your browser is no longer supported. Please, upgrade your browser.
Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-2.14 Insider Own0.10% Shs Outstand123.23M Perf Week1.45%
Market Cap4.91B Forward P/E- EPS next Y-2.26 Insider Trans-67.23% Shs Float120.86M Perf Month27.03%
Income-238.50M PEG- EPS next Q-0.65 Inst Own99.20% Short Float19.02% Perf Quarter41.21%
Sales5.40M P/S909.39 EPS this Y-71.80% Inst Trans2.59% Short Ratio9.53 Perf Half Y23.37%
Book/sh4.92 P/B8.10 EPS next Y3.40% ROA-54.70% Target Price42.25 Perf Year112.76%
Cash/sh4.78 P/C8.34 EPS next 5Y15.30% ROE-58.50% 52W Range17.02 - 42.49 Perf YTD38.18%
Dividend- P/FCF- EPS past 5Y-43.90% ROI- 52W High-6.21% Beta3.95
Dividend %- Quick Ratio15.30 Sales past 5Y- Gross Margin74.50% 52W Low134.14% ATR1.43
Employees340 Current Ratio15.40 Sales Q/Q13407.70% Oper. Margin- RSI (14)70.51 Volatility3.50% 4.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-57.80% Profit Margin- Rel Volume0.94 Prev Close38.88
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 AMC Payout- Avg Volume2.41M Price39.85
Recom2.20 SMA206.73% SMA5021.92% SMA20025.10% Volume2,262,287 Change2.49%
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-30-16Reiterated Piper Jaffray Overweight $39 → $44
Feb-08-16Initiated BofA/Merrill Buy $40
Jan-22-16Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Upgrade Piper Jaffray Neutral → Overweight $48
Aug-07-15Reiterated Needham Buy $38 → $49
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
Apr-16-15Initiated Leerink Partners Outperform $48
Mar-12-15Reiterated Needham Buy $40 → $38
Feb-24-15Initiated H.C. Wainwright Buy $50
Feb-06-15Resumed ROTH Capital Buy $42
Dec-22-14Reiterated Needham Buy $26 → $40
Aug-07-13Reiterated Needham Buy $16 → $26
Aug-07-13Reiterated Ladenburg Thalmann Buy $15 → $24
Aug-07-13Downgrade MLV & Co Buy → Hold $18 → $20
Feb-27-17 09:00AM  ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017 Business Wire
Feb-24-17 01:15PM  Will Acadia Beat Estimates Again? Maybe. at Investopedia
Feb-23-17 04:16PM  ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
Feb-21-17 09:00AM  ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017 Business Wire
Feb-17-17 07:44AM  Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
Feb-16-17 02:31PM  Acadia Pharmaceuticals Surge Higher Is More Than M&A Rumors at Investopedia
Feb-15-17 05:03PM  Price Bump From M&A Rumors Earns Acadia A Vetr Downgrade
02:44PM  Two Great Stock Ideas in the IBB Biotech ETF at Investopedia
08:41AM  Caution: Acadia Pharmaceuticals Is Overvalued at Motley Fool
Feb-12-17 07:43AM  A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease at Motley Fool
Feb-06-17 09:03AM  The Market In 5 Minutes: One For The Thumb
Feb-03-17 01:29PM  Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet
Feb-02-17 10:53AM  Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys at Motley Fool
10:45AM  Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys at Motley Fool
Jan-31-17 09:30AM  Biotech Acquisitions on the Rise in 2017: Latest Reports on Antares Pharma and ACADIA Pharmaceuticals Accesswire +6.10%
08:12AM  How Risky Is Acadia Pharmaceuticals Stock? at Motley Fool
Jan-23-17 02:16PM  Top Biotech Stocks to Buy in 2017 at Motley Fool
Jan-14-17 08:25AM  Why Acadia Pharmaceuticals Inc. Stock Slipped 19% in 2016 at Motley Fool
Jan-08-17 12:12PM  Top Stocks to Buy in 2017 at Motley Fool
11:43AM  3 Companies Whose Sales Could Double in 2017 at Motley Fool
Jan-06-17 09:10AM  Acadia Pharmaceuticals' Alzheimer's Data Raises Some Questions at Motley Fool
Jan-05-17 04:51PM  3 ideas to improve waiting for your trades
11:13AM  #1 issue top traders want to fix in 2017 on our prop desk
09:13AM  The Market In 5 Minutes: Jobless Claims Fall Again, Retailers Struggle
Jan-04-17 06:17PM  Why Encana, Acadia Pharmaceuticals, and Tenet Healthcare Jumped Today at Motley Fool +11.02%
04:43PM  Here's Why Acadia Pharmaceuticals Inc. Stock Is Up Today at Motley Fool
09:15AM  Biotech Stocks to Watch in 2017 ACADIA Pharmaceuticals and Exelixis Accesswire
Jan-03-17 09:00AM  ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017 Business Wire
Dec-28-16 07:18AM  Vetr Still Bullish On Acadia Despite Downgrade
Dec-27-16 08:52AM  4 Biotech Stocks to Buy in January at Motley Fool
Dec-24-16 09:51AM  3 Companies Whose Revenue Could Double in 2017 at Motley Fool
Dec-21-16 10:07AM  ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint
09:15AM  Today's Reports on Biotech Movers ACADIA Pharmaceuticals and Conatus Pharmaceuticals Accesswire
Dec-20-16 11:22PM  Acadia Jumps Following Phase II Alzheimer's Study at Investopedia +12.35%
02:52PM  Why ACADIA Pharmaceuticals Inc. Is Soaring Today at Motley Fool
12:16PM  Tesla Motors Inc (TSLA), Netflix, ACADIA Pharmaceuticals: This Hedge Fund Managers Top Stock Picks for 2017 at Insider Monkey
09:48AM  Acadia Pharma Takes Low Road to Justify Drug Push Into Alzheimer's Psychosis
09:22AM  UPDATE 1-Acadia says Alzheimer's disease psychosis drug clears study
08:30AM  ACADIA Pharmaceuticals Conference Call to Discuss Top-Line Results From Phase II Study With Pimavanserin for AD Psychosis scheduled for 8:30 am ET today
07:40AM  Alzheimer's disease psychosis drug clears mid-stage study -Acadia
07:26AM  ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimers Disease Psychosis Business Wire
Dec-19-16 11:26AM  ACADIA Pharmaceuticals Inc.'s Stock Has Fallen 27% in 2016 -- Have We Hit Bottom? at Motley Fool
10:25AM  ACADIA Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACAD) : December 19, 2016
Dec-16-16 04:59PM  ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
07:10AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACAD-US : December 16, 2016
Dec-10-16 11:05AM  3 Beaten-Up Biotech Stocks: Are They Bargains? at Motley Fool
Dec-06-16 08:16AM  What's behind put volume in Acadia
Dec-05-16 09:01AM  Here's Why ACADIA Pharmaceuticals Jumped 17.7% in November at Motley Fool
07:06AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACAD-US : December 5, 2016
Dec-01-16 09:00AM  ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder Business Wire
Nov-30-16 12:34PM  3 Biotechs With Save-the-Date Catalysts on Tap at Motley Fool
Nov-28-16 08:42AM  Here is What Hedge Funds Think About ACADIA Pharmaceuticals Inc. (ACAD) at Insider Monkey
Nov-23-16 10:29AM  5 Biotech Stocks George Soros Is Buying at Motley Fool +5.61%
07:32AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : November 23, 2016
Nov-21-16 07:03AM  Ready to Get In on Biotech? Check Out These 3 Stocks at Motley Fool
Nov-16-16 01:04PM  ACADIA PHARMACEUTICALS INC Financials
09:16AM  ACADIA Starts Phase II Schizophrenia Study on Pimavanserin
08:15AM  Blog Coverage Viking Presents New Clinical Data on VK2809 Accesswire
Nov-15-16 03:19PM  Johnson & Johnson (JNJ), ACADIA Pharmaceuticals Inc. (ACAD): Healthcare Experts at March Altus Like These and Other Healthcare Stocks Prospects at Insider Monkey
09:00AM  ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia Business Wire
Nov-11-16 04:08PM  Acadia Faces Education Battle With Parkinson's Drug: Goldman
07:53AM  Coverage initiated on ACADIA Pharmaceuticals by Goldman
07:14AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACAD-US : November 11, 2016
Nov-10-16 11:56AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : November 10, 2016
Nov-09-16 10:16AM  ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 +7.56%
Nov-08-16 05:41PM  Here's What Caused ACADIA Pharmaceuticals to Drop 27% in October at Motley Fool +16.75%
03:37PM  Acadia Shares Soar as Nuplazid Sales Easily Top Estimates
11:40AM  Why Acadia Pharmaceuticals Stock Is Surging Today at Motley Fool
11:05AM  Acadia Pharmaceuticals Jumps on Incredible Earnings
10:55AM  Acadia's Valuation Looks Pretty Attractive Right Now: Bank Of America Upgrades To Buy
08:15AM  Analysts' Actions -- Bank of America, Depomed, Hertz, AT&T and More
Nov-07-16 08:37PM  Edited Transcript of ACAD earnings conference call or presentation 7-Nov-16 10:00pm GMT +5.99%
05:48PM  Acadia reports 3Q loss
05:01PM  Acadia Pharma's sales come twice as much as expected at MarketWatch
05:00PM  ACADIA Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
04:36PM  ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:05PM  ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results Business Wire
07:07AM  Q3 2016 ACADIA Pharmaceuticals Inc Earnings Release - After Market Close
Nov-04-16 04:39PM  Arena (ARNA) Q3 Earnings: Will the Stock Pull a Surprise?
03:57PM  Will Kite Pharma (KITE) Stock Surprise Post Q3 Earnings?
08:54AM  Drug Stocks Earnings Roster for Nov 7: HZNP, ACAD & More
Nov-03-16 06:27PM  What to Expect from Repros (RPRX) This Earnings Season -5.14%
09:00AM  ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia Business Wire
Nov-02-16 09:50AM  9 Biotech Stocks to Put on Your Radar at Kiplinger
Nov-01-16 09:00AM  ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016 Business Wire
Oct-31-16 09:23AM  ACADIA Pharma (ACAD): Will It Disappoint in Q3 Earnings?
09:00AM  ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimers Disease Agitation Business Wire
Oct-28-16 08:36AM  3 Charts That Show Why to Buy ACADIA Pharmaceuticals Stock at Motley Fool
Oct-19-16 10:40AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : October 19, 2016
Oct-11-16 09:00AM  ACADIA Pharmaceuticals Receives California Life Sciences Associations 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID Business Wire
Oct-06-16 08:43PM  These 2 Biotechs Could Vanish by 2018 at Motley Fool
Oct-03-16 03:13PM  3 Top Biotech Stocks to Buy in October at Motley Fool
Sep-29-16 09:00AM  The Market In 5 Minutes: OPEC's Deal And Gary Johnson's Moment
08:31AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : September 29, 2016
Sep-23-16 04:07PM  Axovant Confidence 'Not Swayed' After Rival Alzheimer's Drug Fails
Sep-22-16 04:40PM  A Critical Couple of Months for Acadia Pharmaceuticals at Motley Fool
Sep-20-16 09:00AM  ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016 Business Wire
Sep-19-16 11:07AM  ACADIA Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACAD) : September 19, 2016
09:00AM  ACADIA Pharmaceuticals Sponsors National Parkinson Foundations Caregiver Summit Business Wire
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 21Option Exercise34.457,856270,6399,527Feb 23 06:01 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 21Sale39.657,856311,4901,671Feb 23 06:01 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 16Option Exercise28.4466,7521,898,34868,423Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 16Sale39.8866,7522,662,1161,671Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 15Option Exercise19.611,70033,3373,371Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 15Sale39.651,70067,4051,671Feb 16 07:06 PM
Baity GlennEVP AND GCFeb 14Option Exercise6.7126,365176,83993,428Feb 16 07:05 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 14Option Exercise19.6187,1281,708,58090,759Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 14Sale39.6989,0883,535,5731,671Feb 16 07:06 PM
Baity GlennEVP AND GCFeb 14Sale39.6626,3651,045,51767,063Feb 16 07:05 PM
Baity GlennEVP AND GCFeb 01Option Exercise1.5521,07832,67198,141Feb 03 06:50 PM
Baity GlennEVP AND GCFeb 01Sale35.1531,0781,092,38267,063Feb 03 06:50 PM
Baity GlennEVP AND GCDec 28Option Exercise1.625,5008,91077,063Dec 29 05:09 PM
Baity GlennEVP AND GCDec 27Option Exercise1.559,80015,19081,363Dec 29 05:09 PM
Baity GlennEVP AND GCDec 27Sale30.469,800298,47471,563Dec 29 05:09 PM
Baity GlennEVP AND GCDec 20Option Exercise1.5510,00015,50081,563Dec 21 07:03 PM
Baity GlennEVP AND GCDec 20Sale30.0010,000300,00171,563Dec 21 07:03 PM
Baity GlennEVP AND GCDec 19Option Exercise1.648,63514,16171,563Dec 21 07:03 PM
Baity GlennEVP AND GCNov 10Option Exercise1.5510,20015,81073,121Nov 14 07:00 PM
Baity GlennEVP AND GCNov 10Sale30.0710,200306,68762,921Nov 14 07:00 PM
HARRIGAN EDMUNDDirectorAug 16Buy32.971,00032,9701,000Aug 18 05:14 PM
BAKER BROS. ADVISORS LPDirectorAug 10Buy33.001,303,03042,999,99022,337,275Aug 12 04:08 PM
Baity GlennEVP AND GCJul 12Option Exercise6.7811,94380,97474,864Jul 13 06:28 PM
Baity GlennEVP AND GCJul 12Sale35.0011,943418,03162,921Jul 13 06:28 PM
Baity GlennEVP AND GCJul 11Option Exercise6.784,05727,50666,978Jul 13 06:28 PM
Baity GlennEVP AND GCJul 11Sale35.004,057142,00162,921Jul 13 06:28 PM
GRAY MARY ANNDirectorJun 07Option Exercise9.0416,637150,398149,476Jun 09 05:28 PM
Iversen Leslie LDirectorApr 18Option Exercise1.7533,69758,97069,824Apr 20 05:37 PM
Iversen Leslie LDirectorApr 18Sale33.5333,6971,129,99936,127Apr 20 05:37 PM
GRAY MARY ANNDirectorApr 07Option Exercise1.33132,839176,600132,839Apr 07 08:27 PM
BAKER BROS. ADVISORS LPDirectorApr 01Buy28.52302,9008,638,57221,167,398Apr 01 04:21 PM
BAKER BROS. ADVISORS LPDirectorMar 31Buy27.21683,64418,601,18020,894,327Apr 01 04:21 PM
BAKER BROS. ADVISORS LPDirectorMar 30Buy25.94462,54612,000,0562,799,646Apr 01 04:21 PM
Baity GlennEVP AND GCMar 02Option Exercise15.377,000107,59069,921Mar 04 04:54 PM
Baity GlennEVP AND GCMar 02Sale20.807,000145,58062,921Mar 04 04:54 PM